S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"

Alimera Sciences (ALIM) Competitors

$3.36
+0.27 (+8.74%)
(As of 12/1/2023 ET)
Compare
Today's Range
$3.12
▼
$3.36
50-Day Range
$2.63
▼
$3.50
52-Week Range
$1.30
▼
$3.90
Volume
9,298 shs
Average Volume
30,365 shs
Market Capitalization
$176.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

ALIM vs. PRLD, ATAI, AEON, RNAC, OCUL, XOMA, FHTX, PBYI, SBTX, and AKBA

Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Prelude Therapeutics (PRLD), Atai Life Sciences (ATAI), AEON Biopharma (AEON), Selecta Biosciences (RNAC), Ocular Therapeutix (OCUL), XOMA (XOMA), Foghorn Therapeutics (FHTX), Puma Biotechnology (PBYI), Silverback Therapeutics (SBTX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.

Alimera Sciences vs.

Alimera Sciences (NASDAQ:ALIM) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.

Prelude Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -29.40%. Alimera Sciences' return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alimera Sciences-29.40% N/A -13.05%
Prelude Therapeutics N/A -53.91%-49.02%

Alimera Sciences received 328 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 57.99% of users gave Alimera Sciences an outperform vote while only 48.98% of users gave Prelude Therapeutics an outperform vote.

CompanyUnderperformOutperform
Alimera SciencesOutperform Votes
352
57.99%
Underperform Votes
255
42.01%
Prelude TherapeuticsOutperform Votes
24
48.98%
Underperform Votes
25
51.02%

Alimera Sciences has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alimera Sciences$54.13M3.25-$18.11M-$2.63-1.28
Prelude TherapeuticsN/AN/A-$115.44M-$2.17-1.49

In the previous week, Alimera Sciences had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 2 mentions for Alimera Sciences and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat Alimera Sciences' score of 0.94 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alimera Sciences Positive
Prelude Therapeutics Very Positive

Alimera Sciences has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Alimera Sciences currently has a consensus target price of $6.50, indicating a potential upside of 93.45%. Prelude Therapeutics has a consensus target price of $6.67, indicating a potential upside of 106.72%. Given Prelude Therapeutics' higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Alimera Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alimera Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Prelude Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

70.3% of Prelude Therapeutics shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 79.5% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alimera Sciences beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.


Get Alimera Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALIM vs. The Competition

Export to Excel
MetricAlimera SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$161.71M$5.74B$4.50B$6.73B
Dividend YieldN/A2.96%2.97%5.01%
P/E Ratio-1.285.7081.5710.80
Price / Sales3.25142.992,579.8657.92
Price / CashN/A18.9483.55132.40
Price / Book3.614.365.185.06
Net Income-$18.11M$200.53M$123.27M$177.09M
7 Day Performance-3.45%4.75%2.68%2.67%
1 Month Performance3.07%7.92%11.36%8.03%
1 Year Performance-6.15%6.02%5.84%2.32%

Alimera Sciences Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRLD
Prelude Therapeutics
2.2883 of 5 stars		$3.23
-6.1%		$6.67
+106.4%		-51.2%$177.09MN/A-1.49122Positive News
Gap Down
ATAI
Atai Life Sciences
2.5046 of 5 stars		$1.07
-4.5%		$12.80
+1,096.3%		-66.5%$177.63M$334,000.00-2.38133Short Interest ↓
Positive News
Gap Up
AEON
AEON Biopharma
0 of 5 stars		$4.70
-3.9%		$18.00
+283.0%		N/A$174.65MN/A0.009Gap Up
RNAC
Selecta Biosciences
0 of 5 stars		$1.16
+3.6%		N/AN/A$180.03M$110.78M-5.2764Upcoming Earnings
Stock Split
Positive News
Gap Down
OCUL
Ocular Therapeutix
1.9963 of 5 stars		$2.19
-6.8%		$14.00
+539.3%		-12.1%$173.93M$51.49M-1.92274Analyst Downgrade
Short Interest ↑
XOMA
XOMA
2.431 of 5 stars		$15.72
+2.9%		$74.00
+370.7%		-33.5%$180.59M$4.41M-5.5912Short Interest ↓
News Coverage
FHTX
Foghorn Therapeutics
2.0135 of 5 stars		$4.11
flat		$14.83
+260.9%		-35.9%$173.51M$32.57M-1.67161Short Interest ↓
News Coverage
Positive News
Gap Down
High Trading Volume
PBYI
Puma Biotechnology
2.2529 of 5 stars		$3.85
-1.0%		$8.00
+107.8%		-17.8%$183.14M$228M48.13192News Coverage
Positive News
SBTX
Silverback Therapeutics
0 of 5 stars		$4.70
-1.7%		N/A-22.3%$169.47MN/A-1.9483
AKBA
Akebia Therapeutics
2.0295 of 5 stars		$0.99
-3.9%		$5.00
+407.6%		+266.3%$185.56M$194.33M-3.08204Analyst Report
News Coverage

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ALIM) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -